Rize Oncology

Rize Oncology is at the forefront of biotechnology research, dedicated to developing innovative solutions for challenging diseases. With a focus on turning the tide on metastasis, Rize Oncology is committed to advancing medical science and improving patient outcomes.

Rize Oncology is currently developing STS-201, a promising small molecule drug candidate for the treatment of soft tissue sarcoma. STS-201 has demonstrated significant potential not only in soft tissue sarcoma but also in other types of cancers and certain proliferative diseases. The unique mechanism of action of STS-201 results in a blockade of cell division, a slowing of tumor proliferation leading to better oxygenation and more efficient drug delivery, increased oxygen in the tumor micro-environment, and the formation of a more complete tumor vasculature.

Rize Oncology's ongoing research aims to bring forth breakthroughs that can transform the landscape of cancer treatment. We invite the manager of Rize Oncology to create a customized and exclusive company showcase and product listing on our platform to further highlight their innovative work.